Alnylam Pharmaceuticals, Inc.
Compositions and methods directed to treating liver fibrosis
Last updated:
Abstract:
The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the COL1A1, TGF-.beta., and SMAD2/3 genes, and methods of using such dsRNA compositions to inhibit expression of COL1A1, TGF-.beta., and SMAD2/3.
Status:
Grant
Type:
Utility
Filling date:
26 Feb 2018
Issue date:
2 Jun 2020